TG Therapeutics logo

TG Therapeutics

TGTX | NASDAQ
Chart Builder DCF Calculator
$62.76
-$1.75 (-2.71%)
At close: Nov 16, 2026, 4:00 PM ET
$62.74
-$0.02 (-0.03%)
After-hours: Nov 16, 2026, 7:30 PM ET
-2.71%

No price chart data available for 1D timeframe.

Rating

Updated: Nov 16, 2026
61.2
Fundamentals Strong
Market Sentiment Bullish
Moat Narrow
Sector Rank #124/1021 (Top 12%)

Key Statistics

Market Data

Market Cap $9.49B
1D Range
62.02 65.34
52W Range
26.94 65.76

Valuation (TTM)

PE 95.09
PB 16.58
EV/EBITDA 50.89

Valuation (NTM)

Forward PE 62.63
Forward PEG -1.32
Price Target $80.50
Loading financial charts...

Profile

Based in New York City and established in 1993, TG Therapeutics, Inc. is a biopharmaceutical company that has advanced to the commercial stage. Its core mission revolves around the acquisition, advanc...

Sector Healthcare
Industry Biotechnology
Employees 399
IPO Date May 3, 2010
Fiscal Year January - December

Latest News

TG Therapeutics: 3 Key Takeaways for Long-Term Investors

2 days ago · fool.com

TG Therapeutics: 3 Key Takeaways for Long-Term Investors
TGTX Q3 Earnings & Revenues Beat Estimates, 2026 View Raised, Stock Up

6 days ago · zacks.com

TGTX Q3 Earnings & Revenues Beat Estimates, 2026 View Raised, Stock Up
TG Therapeutics, Inc. (TGTX) Q3 2026 Earnings Call Transcript

7 days ago · seekingalpha.com

TG Therapeutics, Inc. (TGTX) Q3 2026 Earnings Call Transcript
What TG Therapeutics (TGTX) Said on Its Q3 Earnings Call

8 days ago · marketbeat.com

What TG Therapeutics (TGTX) Said on Its Q3 Earnings Call
TG Therapeutics (TGTX) Reports Q3 Earnings: What Key Metrics Have to Say

8 days ago · zacks.com

TG Therapeutics (TGTX) Reports Q3 Earnings: What Key Metrics Have to Say
TG Therapeutics (TGTX) Beats Q3 Earnings and Revenue Estimates

8 days ago · zacks.com

TG Therapeutics (TGTX) Beats Q3 Earnings and Revenue Estimates
TG Therapeutics Reports Third Quarter 2026 Financial Results and Raises Full-Year Revenue Guidance

8 days ago · businesswire.com

TG Therapeutics Reports Third Quarter 2026 Financial Results and Raises Full-Year Revenue Guidance
TG Therapeutics to Host Conference Call on Third Quarter 2026 Financial Results and Business Update

15 days ago · businesswire.com

TG Therapeutics to Host Conference Call on Third Quarter 2026 Financial Results and Business Update
TG Therapeutics (TGTX) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release

22 days ago · zacks.com

TG Therapeutics (TGTX) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release
TGTX Stock Rises 60% in 6 Months: Here's What You Should Know

1 month ago · zacks.com

TGTX Stock Rises 60% in 6 Months: Here's What You Should Know

Earnings

Latest Earnings
Nov 9, 2026
EPS
$0.35
Miss -2.59%
REV
$259.94M
Beat +5.89%
Next Earnings
Feb 25, 2027
EPS Est
Pro
Rev Est
Pro
Earnings Details ➞

Analyst Summary

# of Analysts
6
Consensus
Buy
Price Target
$80.50
Upside
+28.27%
Buy (4)
Hold (1)
Sell (1)
Analyst Details ➞

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.